Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
42
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Offerpad Solutions
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Digital Transformation And Urbanization Will Boost Online Home Transactions
Key Takeaways Scalable, tech-driven offerings and a seamless hybrid model position Offerpad for accelerated revenue growth and industry-leading margin expansion as digital adoption in real estate rises. Cross-sell opportunities and enhanced liquidity enable Offerpad to capture a larger share of the transaction value chain and pursue aggressive market expansion with reduced risk.
View narrative
US$1.40
FV
2.1% overvalued
intrinsic discount
33.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Rani Therapeutics Holdings
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Needle-Free Oral Biologics Will Serve Aging Global Demand
Key Takeaways Rani's oral therapy platform offers a significant adoption advantage and margin potential due to its non-invasive delivery and superior performance versus injections. Advancements in manufacturing and partnerships position the company for strong long-term growth while reducing reliance on dilutive financing.
View narrative
US$12.00
FV
95.4% undervalued
intrinsic discount
283.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Mersana Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Precision Medicine And Global Aging Will Open Opportunities
Key Takeaways Emi-Le's broader therapeutic potential, enhanced dosing strategies, and demographic trends position Mersana for outsized growth and margin expansion in breast cancer markets. Strategic collaborations and proprietary ADC platforms diversify revenue, reduce cash burn, and support long-term growth in precision medicine.
View narrative
US$250.00
FV
97.1% undervalued
intrinsic discount
-4.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Kinross Gold
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Persistent Inflation And Uncertainty Will Sustain High Gold Prices
Key Takeaways Strong gold prices, inflation, and geopolitical uncertainty drive high margins and offer positive prospects for continued revenue, earnings growth, and cash flow resilience. Expansion projects, efficiency gains, and organic reserve growth support longer mine life, cost reduction, and stable long-term returns for shareholders.
View narrative
CA$25.20
FV
6.1% overvalued
intrinsic discount
1.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
31
users have followed this narrative
2 days ago
author updated this narrative
Altamir
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
6X Leverage And Tech Exposure Will Depress Valuations
Key Takeaways Overreliance on tech sector growth and divestment-driven gains leaves earnings and portfolio value vulnerable to market shifts and normalization. Challenging exit environment, high leverage, and increased regulatory scrutiny threaten future private equity activity, margin expansion, and capital inflows.
View narrative
€28.50
FV
1.4% overvalued
intrinsic discount
-14.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
GT
Goodyear Tire & Rubber
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Global Vehicle Trends Will Drive Premium Tire Demand
Key Takeaways Focus on premium tire segments, operational modernization, and innovation is expected to boost margins and competitive positioning as consumer and regulatory trends evolve. Asset sales and debt reduction initiatives aim to strengthen the balance sheet, cut financial risk, and support renewed investment in growth.
View narrative
US$12.17
FV
30.2% undervalued
intrinsic discount
0.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
Updated
narrative
Helios Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Electrification And Digital Solutions Will Drive Future Industrial Progress
Key Takeaways Rapid product innovation and industry electrification position Helios for growth, margin expansion, and increased market share in evolving automation and control solutions. Operational restructuring, diversified revenue streams, and improved capital allocation enhance financial stability, efficiency, and potential for higher long-term earnings.
View narrative
US$57.40
FV
10.5% undervalued
intrinsic discount
4.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
3 days ago
author updated this narrative
GRAIL
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
FDA Approval And NHS Studies Will Transform Cancer Detection
Key Takeaways Positive clinical results and expanding commercial adoption of Galleri position GRAIL for strong regulatory momentum, payer support, and accelerated, diversified revenue growth. Enhanced process scalability and disciplined cost control are improving margins and reducing losses, while global partnerships and demographic trends drive long-term opportunity.
View narrative
US$40.50
FV
19.9% undervalued
intrinsic discount
20.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
2 days ago
author updated this narrative
THG
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
FTSE 250 Transfer And Demerger Will Strengthen Business Performance
Key Takeaways THG's FTSE 250 Index move and demerger are set to boost liquidity and focus, enhancing revenue growth and EBITDA margins. Brand repositioning and strategic partnerships in THG Nutrition and Beauty prioritize high-margin areas, driving growth and diversifying revenue streams.
View narrative
UK£0.42
FV
24.6% undervalued
intrinsic discount
2.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
2 days ago
author updated this narrative
Value any company in seconds
Popular companies